Inflammatory bowel diseases: meeting of the European Crohn's Colitis Organization, 1-3 March 2007, Innsbruck, Austria.
Inflammatory bowel diseases affect > 1 million Europeans, and mostly people at a young age. Although these diseases are still increasing worldwide, especially in children and adolescents, progress in the pathophysiology and treatment of these diseases in recent years has been tremendous. In particular, anti-TNF-alpha agents dramatically changed the management of these diseases. The European Crohn's Colitis Organization recently held its second annual meeting in Innsbruck, Austria dealing with both new basic and clinical developments in the field.
Tilg
Herbert
H
Medical University Innsbruck, Department of Medicine, Anichstrasse 35, 6020 Innsbruck, Austria. herbert.tilg@i-med.ac.at
D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001317:Austria; D003092:Colitis / Q000188:drug therapy* / Q000378:metabolism; D003424:Crohn Disease / Q000188:drug therapy* / Q000378:metabolism; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D005060:Europe; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000378:metabolism; D000069285:Infliximab; D012955:Societies, Medical; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000378:metabolism
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab